Preventing and treating the side effects of testosterone inactivating pharmaceuticals in men with prostate cancer

Seminars in Preventive and Alternative Medicine

Volumn 2, Issue 2, 2006, Pages 76-84

  Guess, Brad W ^a   Scholz, Mark C ^b   Lam, Richard Y ^b  

^a Prostate Cancer Research Institute   (United States)

^b Prostate Oncology Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CITRATE CALCIUM; EULIXEN; FLUTAMIDE; GLUCOSAMINE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHYLPHENIDATE; NILANDRONE; NILUTAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL; TADALAFIL; TAMOXIFEN CITRATE; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASTAS IMPLANT; VIADUR IMPLANT; VITAMIN D;

ACUPUNCTURE; ANEMIA; ARTHRALGIA; BLOOD CLOT; BLOOD PRESSURE; BLOOD PRESSURE FLUCTUATION; BODY FAT; BONE DENSITY; BREAST TENDERNESS; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; COUGHING; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRY SKIN; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPNEA; EJACULATION DISORDER; EMOTIONAL STRESS; ERECTILE DYSFUNCTION; EVENING DOSAGE; FATIGUE; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HAIR LOSS; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MEMORY DISORDER; METABOLIC DISORDER; MONOTHERAPY; MUSCLE ATROPHY; MUSCLE TRAINING; NEUROLOGIC DISEASE; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PENIS DISEASE; PENIS NOCTURNAL TUMESCENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RESIDUAL URINE; REVIEW; SEXUAL SATISFACTION; SIDE EFFECT; URINARY DYSFUNCTION; URINARY FREQUENCY; URINARY URGENCY; WEIGHT GAIN;

EID: 38849171035     PISSN: 15564061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spre.2005.12.003     Document Type: Review

References (75)

1. Denmeade S, Isaacs J: Development of prostate cancer treatment: The good news. Prostate 58:211-224, 2004
2. Grossfeld G, Small E, Carroll P: Intermittent androgen deprivation for clinically localized prostate cancer. Urology 51:137-144, 1998
3. Crook J, Szumacher E, Malone S, et al: Intermittent androgen suppression in the management of prostate cancer. Urology 53:520-524, 1999
4. Strum S, Scholz M, McDermed J: Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy. The Oncologist 5:45-52, 2000
5. Grossfeld G, Chaudhary U, Reese D, et al: Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58:240-245, 2001
6. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
7. Pilepich M, Winter K, Lawton C, et al: Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate: Long-term results of phase III RTOG study 85-31 [abstract]. Int J Radiat Oncol Biol Phys 57:S172-S173, 2003
8. Messing E, Manola J, Sarosdy, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer: Results at 10 years of EST 3886 [abstract 1480]. J Urol 169:396, 2003
9. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials. Lancet 355:1491-1498, 2000
10. Huggins C, Hodges C: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma on the prostate Cancer Res 1:293-297, 1941
11. Chen A, Petrylak D: Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep 6:209-215, 2004
12. Holzbeierlein J, Castle E, Thrasher J: Complications of androgen deprivation therapy for prostate cancer. Clin Prostate Cancer 2:147-152, 2003
13. Herr H, O'Sullivan M: Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen deprivation therapy. J Urol 163:1743-1746, 2000
14. Clark J, Inui T, Silliman RA, et al: Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 21:3777-3784, 2003
15. McDermed J, Strum S, Scholz, M: The androgen deprivation syndrome (ADS): The incidence and severity in prostate cancer (PC) patients (PTS) receiving hormone blockade (HB). Proc Am Soc Clin Oncol 17:316a, 1998
16. Caubet J, Tosteson T, Dong E, et al: Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49:71-78, 1997
17. Klotz P, Schellmammer P, Carroll K: A re-assessment of the role of combined androgen blockade for advanced prostate cancer. Br J Urol Int 93:1177-1182, 2004
18. Whittington R, Broderick G, Arger P, et al: The effects of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44:1107-1110, 1909
19. Kucway R, Vicini F, Huang R, et al: Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167:2443-2447, 2002
20. Johannsson G, Gibney J, Wolthers T, et al: Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endrocrinol Metab 90:3989-3994, 2005
21. Feldman H, Goldstein I, Hatzichristou D, et al: Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 151:54-61, 1994
22. Rosen R, Cappelleri J, Smith M, et al: Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319, 1999
23. Padma-Nathan H, McCullough A, Giuliano F, et al: Postoperative nightly administrations of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy [abstract]. Prog Urol 13:231, 2003 (suppl 2)
24. Sommer F, Men's Health Study Group: What are the long term effects on erectile function of taking sildenafil on a daily basis [abstract]? J Urol 171:239, 2004 (suppl 4)
25. Baltaci S, Aydos K, Kosar A, et al: Treating erectile dysfunction with a vacuum tumescence device: Retrospective analysis of acceptance and satisfaction. Br J Urol 76:757-760, 1995
26. Turner L, Althof S, Levine S, et al: Treating erectile dysfunction with external vacuum devices: Impact upon sexual psychological and marital functioning. J Urol 144:79-82, 1990
27. Scholz M, Strum S: RE: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 161:1914-1915, 1999
28. Raina R, Agarwal A, Allamaneni S, et al: Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 65:360-364, 2005
29. Padma-Nathan H, Hellstrom W, Kaiser F, et al: Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336: 1-7, 1997
30. Shabsign R, Padma-Nathan H, Gittleman M, et al: Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: A comparative, randomized, crossover, multicenter study. Urology 55:109-113, 2000
31. Gutierrez P, Hernandex P, Mas M: Combining programmed intracavernous PGE-1 injections and sildenafil on demand to salvage sildenafil non-responders. Int J Impot Res 17:354-358, 2005
32. Epperly T, Moore K: Diagnosis, prevention, and treatment of osteoporosis in men. J Gend Specif Med 5:33-38, 2002
33. Daniell H, Dunn S, Ferguson D, et al: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181-186, 2000
34. Goldray D, Weisman Y, Jaccard N, et al: Decreased bone density in elderly men treated with a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 76:288-290, 1993
35. Oefelein M, Ricchuiti V, Conrad W, et al: Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk for patients with prostate cancer. J Urol 166:1724-1728, 2002
36. Shahinian V, Kuo Y, Freeman J, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005
37. Smith M, McGovern F, Fallon M, et al: Low bone-mineral density in hormone-naive men with prostate carcinoma. Cancer 91:2238-2245, 2001
38. Smith M, McGovern F, Zietman A, et al: Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 345:948-955, 2001
39. Smith M, Eastham J: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol 169:2008-2012, 2003
40. Lam R, Scholz M, Guess B, et al: Oral bisphosphonates for the prevention of androgen deprivation therapy-associated bone loss: Preliminary findings [abstract 4749], in Proceedings of ASCO Annual Meeting. Cambridge, MA, Database Publishing Group Inc, 2004, p 442
41. Orwoll E, Ettinger M, Weiss S, et al: Alendronate for the treatment of osteoporosis in men, N Engl J Med 343:604-610, 2000
42. Arnaud C: Osteoporosis: Using "bone markers" for diagnosis and monitoring. Geriatrics 51:24-30, 1996
43. Snyder P, Peachey H, Hannoush P, et al: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84:2647-2653, 1999
44. Segal R, Reid R, et al: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653-1659, 2003
45. Karling P, Hammar M, Varenhorst E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 152:1170-1173, 1994
46. Kouriefs C, Georgiou M, Ravi R: Hot flushes and prostate cancer: Pathogenesis and treatment. Br J Urol Int 89:379-383, 2002
47. Mohad M: Promoting general health during androgen deprivation therapy (ADT): A rapid 10-step review for your patients, Urol Oncol 23: 56-64, 2005
48. Hammar M, Frisk J, Grimas O, et al: Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: A pilot study. J Urol 161:853-856, 1999
49. Albertazzi P, Pansini F, Bonaccorsi G, et al: The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 91:6-11, 1998
50. Barton D, Loprinzi C, Quella S, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495-500, 1998
51. Pockaj B, Loprinzi C, Sloan J, et al: Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 22:515-521, 2004
52. Langenstroer P, Kramer B, Cutting B, et al: Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 174: 642-645, 2005
53. Loprinzi C, Michalak J, Quella S, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347-352, 1994
54. Sartor O, Eastham J: Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 92:415-416, 1999
55. Smith JJR: A prospective comparison of treatments of symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. J Urol 152:132-134, 1994
56. Quella S, Loprinzi C, Sloan J, et al: Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 162:98-102, 1999
57. Jeffery S, Pepe J, Popovich L, et al: Gabapentin for hot flashes in prostate cancer. Ann Pharmacother 36:433-436, 2002
58. McLeod D, Iversen P: Gynecomastia in patients with prostate cancer: A review of treatment options. Urology 56:713-720, 2000
59. Iversen P, Tyrrell C, Kaisary A, et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advance prostate cancer: 6.3 years of follow-up. J Urol 164:1579-1582, 2000.
60. Boccardo F, Rubagotti A, Battaglia M, et al: Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23:808-815, 2005
61. Widmark A, Fossa S, Lundmo P, et al: Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 61:145-151, 2003
62. Nishiyama T, Ishizake F, Anraku T, et al: The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90:657-660, 2005
63. Smith M, Finkelstein J, McGovern F, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603, 2002
64. Smith J, Bennett S, Evancs L, et al: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267, 2001
65. Fonseca R, Rajkumar S, White W, et al: Anemia after orchiectomy. Am J Hematol 59:230-233, 1998
66. Strum S, McDermed J, Scholz M, et al: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933-941, 1997
67. Cherrier M, Asthana S, Plymate S: Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57:80-88, 2001
68. Salminen E, Portin R, Korpela J, et al: Androgen deprivation and cognition in prostate cancer. Br J Cancer 89:971-976, 2003
69. Cherrier M, Rose A, Higano C: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patient with prostate cancer. J Urol 170:1808-1811, 2003
70. Folstein M, Folstein S, McHugh P: "Mini-mental state:" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975
71. U.S. Preventive Services Task Force of the Agency for Healthcare Research and Quality: Screening for Depression: Recommendations and Rationale. Rockville, MD: USPSTF, 2002.
72. Whooley M, Avins A, Miranda J, et al: Case-finding instruments for depression: Two questions are as good as many. J Gen Intern Med 12:439-445, 1997
73. Pfitzenmeyer P, Foucher P, Piard F, et al: Nilutamide pneumonitis: A report on eight patients. Thorax 47:622-627, 1992
74. Schellhammer P, Sharifi R, Block N, et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double blind, randomized, multicenter trial. Urology 50:330-336, 1997
75. Milk Thistle. Effects on Liver Disease and Cirrhosis and Clinical Adverse Effects. Summary, Evidence Report/Technology Assessment: Number 21, September 2000. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/clinic/epcsums/ milksom.htm. Accessed December 12, 2005